BCRX * Panoramica delle azioni BioCryst Pharmaceuticals, Inc. è un'azienda biotecnologica che sviluppa terapie orali a base di piccole molecole e proteine per il trattamento di malattie rare. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
BioCryst Pharmaceuticals, Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per BioCryst Pharmaceuticals Prezzi storici delle azioni Prezzo attuale dell'azione US$155.00 Massimo di 52 settimane US$170.00 Minimo di 52 settimane US$98.29 Beta 1.75 Variazione di 1 mese 0% Variazione a 3 mesi 0% Variazione di 1 anno n/a Variazione a 3 anni -50.00% Variazione a 5 anni 151.99% Variazione dall'IPO 127.77%
Notizie e aggiornamenti recenti
BioCryst Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 24, 2025 Feb 10
BioCryst Pharmaceuticals, Inc. Provides Preliminary Unaudited Total Revenue Guidance for the Fourth Quarter and Year 2024 and Year 2025 Jan 11
Insufficient new directors Jan 08
BioCryst Pharmaceuticals, Inc. Launches ORLADEYO® (berotralstat) in Ireland Nov 21
Insufficient new directors Nov 12
BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026 Nov 05 Vedi altri aggiornamenti
BioCryst Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 24, 2025 Feb 10
BioCryst Pharmaceuticals, Inc. Provides Preliminary Unaudited Total Revenue Guidance for the Fourth Quarter and Year 2024 and Year 2025 Jan 11
Insufficient new directors Jan 08
BioCryst Pharmaceuticals, Inc. Launches ORLADEYO® (berotralstat) in Ireland Nov 21
Insufficient new directors Nov 12
BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026 Nov 05
BioCryst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 21
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting Orladeyo (Berotralstat) Oct 14
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome Oct 02
BioCryst Pharmaceuticals, Inc. Announces Successfully Completed Negotiations with the Pan-Canadian Pharmaceutical Alliance (Pcpa) for Oral, Once-Daily Prorladeyo® (Berotralstat) Sep 17
Biocryst Pharmaceuticals, Inc. Appoints Donald Fong as Chief Medical Officer Sep 05
BioCryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024 Aug 05
BioCryst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Jul 22
BioCryst Pharmaceuticals, Inc. Announces Federal Commission for Protection Against Health Risks in Mexico Grants Approval for Oral, Once-Daily ORLADEYO May 15
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO May 10
Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024 May 09
Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024 May 08
BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024 Apr 28
BioCryst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 06, 2024 Apr 23
BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency Apr 17
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024 Feb 29
Full year 2023 earnings released: US$1.18 loss per share (vs US$1.33 loss in FY 2022) Feb 27
Forecast to breakeven in 2026 Feb 23
BioCryst Launches Orladeyo (Berotralstat) in Italy Feb 20
BioCryst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 26, 2024 Feb 13
Forecast to breakeven in 2026 Jan 12
BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024 Jan 06
BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat) Dec 19
Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023 Dec 01
Biocryst Announces Approval of Orladeyo®? (Berotralstat) by the National Administration of Drugs, Foods, and Medical Devices in Argentina Nov 29
BioCryst Pharmaceuticals, Inc. Announces Spanish Ministry for Health Grants Marketing Authorization for Oral, Once-Daily ORLADEYO Nov 22
BioCryst Pharmaceuticals, Inc. Presents New Real-World Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-Inhibitor Following Long-Term Treatment with ORLADEYO(R) (berotralstat) Nov 11
BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2023 Nov 03
BioCryst Pharmaceuticals, Inc. to Present New ORLADEYO®? (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology Oct 28
Biocryst Pharmaceuticals, Inc. Begins Enrollment in Proof-Of-Concept Trial to Confirm Safe, Effective, Once-Daily Dose of Oral Factor D Inhibitor, Bcx10013 Oct 27
BioCryst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 20
INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec Sep 19
Second quarter 2023 earnings released: US$0.40 loss per share (vs US$0.32 loss in 2Q 2022) Aug 04
BioCryst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 23
Biocryst Pharmaceuticals, Inc. Announces Executive Changes Jul 12
BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Public Health Institute of Chile May 23
BioCryst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 21, 2023 Feb 08
BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating Orladeyo(R) (Berotralstat) in Pediatric Patients with Hereditary Angioedema Jan 27
BioCryst Pharmaceuticals, Inc. Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases Jan 10
High number of new directors Dec 07
BioCryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) by the Israeli Ministry of Health Nov 29
High number of new directors Nov 16
Biocryst Presents Real-World Data Showing Rapid and Sustained Hae Attack Rate Reduction After Beginning Orladeyo® (Berotralstat), Regardless of Prior Prophylactic Therapy Nov 11
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022 Nov 02
BioCryst Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022 Oct 19
High number of new directors Oct 03
BioCryst Pharmaceuticals, Inc. Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold as Chief Medical Officer Sep 15
FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva Sep 01
Biocryst Presents Data Demonstrating >99% Suppression of Alternative Pathway Complement Activity with Bcx9930 in C3g Patients Aug 27
Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) in Saudi Arabia Aug 19
BioCryst Pharmaceuticals, Inc. Resumes Enrollment in BCX9930 Clinical Program Aug 06
Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.24 loss in 2Q 2021) Aug 05
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022 Aug 05
High number of new directors Aug 04
BioCryst Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 22
BioCryst Pharmaceuticals, Inc. Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat) Jul 02
BioCryst Announces ORLADEYO(R) (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022 Jun 23
Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 Inhibitor, BCX9250 Jun 10
Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 Inhibitor, BCX9250 Jun 09
Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo(R) (Berotralstat) by Swissmedic Jun 08
Biocryst Announces Health Canada Has Authorized Orladeyo® (Berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks Jun 07
High number of new directors May 30
First quarter 2022 earnings released: US$0.40 loss per share (vs US$0.36 loss in 1Q 2021) May 06
BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2022 May 06
European Medicines Agency Grants PRIME Designation to BioCryst Pharmaceuticals, Inc.'s ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva Apr 28
High number of new directors Apr 27
BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2022 Apr 26
BioCryst Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 22
BioCryst Pharmaceuticals, Inc. Pauses Enrollment in BCX9930 Clinical Trials Apr 09
High number of new directors Apr 08
Biocryst Pharmaceuticals, Inc. Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among Hae Patients Following Long-Term Treatment with Orladeyo Feb 25 BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022
BioCryst Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 10
BioCryst Appoints Machelle Sanders to Board of Directors Feb 09
High number of new directors Jan 29
BioCryst Pharmaceuticals, Inc. Provides ORLADEYO Net Revenue and Peak Sales Guidance for Full Year 2022 Jan 12
BioCryst Pharmaceuticals, Inc. Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH Jan 09
BioCryst Pharmaceuticals, Inc Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH Dec 01
Director recently bought Mex$2.0m worth of stock Nov 26
High number of new directors Nov 22
Independent Director recently sold Mex$899k worth of stock Sep 15
High number of new directors Sep 15
High number of new directors Sep 07
BioCryst Pharmaceuticals, Inc. Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic Aug 26
Senior VP & Chief Business Officer Megan Sniecinski has left the company Aug 14
Second quarter 2021 earnings released: US$0.24 loss per share (vs US$0.24 loss in 2Q 2020) Aug 06
Director Vincent Milano has joined 3rd company board Aug 03
Director Vincent Milano has joined 3rd company board Aug 03
Director Vincent Milano has joined 3rd company board Aug 03
BioCryst Pharmaceuticals, Inc. Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients with PNH Jul 16 BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell Microcap Growth Index Rendimenti per gli azionisti BCRX * MX Biotechs MX Mercato 7D 0% 0% 0% 1Y n/a 0% 0%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: Dati insufficienti per determinare come si è comportato BCRX * rispetto al settore MX Biotechs.
Rendimento vs Mercato: Dati insufficienti per determinare la performance di BCRX * rispetto al mercato MX.
Volatilità dei prezzi Is BCRX *'s price volatile compared to industry and market? BCRX * volatility BCRX * Average Weekly Movement n/a Biotechs Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di BCRX * è stato volatile rispetto al mercato MX.
Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di BCRX * nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 1986 536 Jon Stonehouse www.biocryst.com
BioCryst Pharmaceuticals, Inc. è una società di biotecnologie che sviluppa terapie orali a base di piccole molecole e proteine per il trattamento di malattie rare. L'azienda commercializza il peramivir iniettabile, un inibitore della neuraminidasi per via endovenosa per il trattamento dell'influenza acuta non complicata, con i nomi RAPIVAB, RAPIACTA e PERAMIFLU, e l'ORLADEYO, un inibitore orale della serina proteasi per il trattamento dell'angioedema ereditario. Sta inoltre sviluppando BCX10013, un inibitore orale del fattore D per le malattie mediate dal complemento.
Mostra di più BioCryst Pharmaceuticals, Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di BioCryst Pharmaceuticals con la sua capitalizzazione di mercato? BCRX * statistiche fondamentali Capitalizzazione di mercato Mex$36.87b Guadagni(TTM ) -Mex$2.55b Ricavi(TTM ) Mex$8.51b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) BCRX * Conto economico (TTM ) Ricavi US$412.58m Costo del fatturato US$197.47m Profitto lordo US$215.11m Altre spese US$338.93m Guadagni -US$123.82m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
Feb 24, 2025
Utile per azione (EPS) -0.60 Margine lordo 52.14% Margine di profitto netto -30.01% Rapporto debito/patrimonio netto -176.9%
Come si è comportato BCRX * nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/02/11 04:09 Prezzo dell'azione a fine giornata 2025/01/07 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github .
Fonti analitiche BioCryst Pharmaceuticals, Inc. è coperta da 30 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Huidong Wang Barclays Tazeen Ahmad BofA Global Research Dae Gon Ha BTIG
Mostra 27 altri analisti 
